EUVIMEDEUVIMED entdecken
Crossref

Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity

Mark E Schnute iD, Huixian Wu iD, John I Trujillo iD, Wei Li, David Jonathan Wasilko, Jennifer Alley, Eric P Arnold, Scott W Bagley iD, Gabriel Berstein, David C Blakemore, Mark W Bundesmann, Gary M Chinigo iD und 33 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01946 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mark E Schnute und 44 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Receptors, CCR6, Drug Discovery. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The G protein-coupled receptor (GPCR) CCR6 mediates the migration of pathogenic immune cells to the site of inflammation in response to the chemokine CCL20. CCR6 is an attractive target for the treatment of chronic autoimmune disease as antagonism of the receptor is expected to block CCL20-mediated immune cell recruitment. High-throughput-screening identified a squaramide-based, allosteric antagonist of CCR6 that potently inhibited CCL20-mediated T cell chemotaxis, but it also inhibited CXCL1-mediated neutrophil chemotaxis through CXCR2 antagonism. Lead optimization achieved differentiation from CXCR2 through identification of a methyl substituent-dependent selectivity switch or “magic methyl for selectivity”. The mechanism for this effect is rooted in different antagonist-induced ligand–receptor behaviors, insurmountable for CCR6 and surmountable for CXCR2. Herein, we report the discovery and preclinical evaluation of the CCR6 antagonist PF-07054894 (18l) which has advanced to clinical trials as a first in class approach targeting the receptor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Interleukin-8BReceptors, CCR6Drug DiscoveryHumansStructure-Activity RelationshipAnimalsChemotaxisT-LymphocytesMiceNeutrophilsChemokine CCL20

Substanzen

Receptors, Interleukin-8BReceptors, CCR6CCR6 protein, humanCXCR2 protein, humanChemokine CCL20

Autor:innen und Institutionen

  • Medicine Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States.
  • Medicine Design, Pfizer Inc, Groton, Connecticut 06340, United States.
  • Inflammation and Immunology Research, Pfizer Inc, Cambridge, Massachusetts 02139, United States.
  • Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom.
  • Drug Product Design, Pfizer Inc, Cambridge, Massachusetts 02139, United States.

ORCID-Profile: Mark E Schnute, Huixian Wu, John I Trujillo, Scott W Bagley, Gary M Chinigo, Chulho Choi, Andrew Flick, Brian S Gerstenberger, Daniel W Kung, James J Mousseau, Arjun Narayanan, Michael J Primiano

Zitieren

APA

Schnute, M. E., Wu, H., Trujillo, J. I., Li, W., Wasilko, D. J., Alley, J., Arnold, E. P., Bagley, S. W., Berstein, G., Blakemore, D. C., Bundesmann, M. W., Chinigo, G. M., Choi, C., Cooke, R., Crouse, K., Dermenci, A., Dickinson, T., Flick, A., Frisbie, R. K., …, & Thorarensen, A. (2025). Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01946

Vancouver

Schnute ME, Wu H, Trujillo JI, Li W, Wasilko DJ, Alley J, et al. Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01946

BibTeX
@article{Schnute2025,
  author = {Schnute, Mark E and Wu, Huixian and Trujillo, John I and Li, Wei and Wasilko, David Jonathan and Alley, Jennifer and Arnold, Eric P and Bagley, Scott W and Berstein, Gabriel and Blakemore, David C and Bundesmann, Mark W and Chinigo, Gary M and Choi, Chulho and Cooke, Robert and Crouse, Kimberly and Dermenci, Alpay and Dickinson, Theresa and Flick, Andrew and Frisbie, Richard K and Garcia-Irizarry, Carmen and Gerstenberger, Brian S and Hepworth, David and Kaila, Neelu and Kung, Daniel W and Lamb, Daniel and Lavergne, Sophie Y and Limburg, David C and Liu, Shenping and Lombardo, Vincent M and Mondal, Prolay K and Mousseau, James J and Narayanan, Arjun and Niljianskul, Nootaree and Nuhant, Philippe and Pan, Senliang and Primiano, Michael J and Rappas, Mathieu and Schmitt, Daniel C and Steyn, Stefanus J and Unwalla, Ray and Vasa, Dipy and Vazquez, Michael L and Vincent, Fabien and Yang, Xiaojing and Thorarensen, Atli},
  title = {Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01946}
}
Kostenlos starten →